EP1658032A1 - Therapeutisches behandlungsgerät - Google Patents
Therapeutisches behandlungsgerätInfo
- Publication number
- EP1658032A1 EP1658032A1 EP04761018A EP04761018A EP1658032A1 EP 1658032 A1 EP1658032 A1 EP 1658032A1 EP 04761018 A EP04761018 A EP 04761018A EP 04761018 A EP04761018 A EP 04761018A EP 1658032 A1 EP1658032 A1 EP 1658032A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatment device
- therapeutic treatment
- frequency band
- sine
- sound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 44
- 238000011282 treatment Methods 0.000 title claims abstract description 38
- 230000005236 sound signal Effects 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 2
- 125000000524 functional group Chemical group 0.000 description 24
- 230000006870 function Effects 0.000 description 14
- 210000003205 muscle Anatomy 0.000 description 12
- 210000000988 bone and bone Anatomy 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 8
- 210000003041 ligament Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 210000001835 viscera Anatomy 0.000 description 5
- 230000010355 oscillation Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 206010033433 Pain in jaw Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 208000024765 knee pain Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 206010038490 Renal pain Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010061373 Sudden Hearing Loss Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000009365 direct transmission Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 210000002745 epiphysis Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006261 foam material Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 208000012285 hip pain Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000036544 posture Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000000724 thymus hormone Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H23/00—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms
- A61H23/02—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive
- A61H23/0218—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive with alternating magnetic fields producing a translating or oscillating movement
- A61H23/0236—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive with alternating magnetic fields producing a translating or oscillating movement using sonic waves, e.g. using loudspeakers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/01—Constructive details
- A61H2201/0119—Support for the device
- A61H2201/0138—Support for the device incorporated in furniture
- A61H2201/0142—Beds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2205/00—Devices for specific parts of the body
- A61H2205/04—Devices for specific parts of the body neck
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2205/00—Devices for specific parts of the body
- A61H2205/08—Trunk
- A61H2205/081—Back
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2205/00—Devices for specific parts of the body
- A61H2205/10—Leg
Definitions
- the invention relates to a therapeutic treatment device according to the preamble of claim 1.
- Therapeutic treatments using manual treatment techniques are well known.
- the hands of the therapist exert tensile and compressive forces to loosen the ligaments and muscles of the patient, which, depending on the indication and treatment technique, has a therapeutic effect, such as mobilizing joints, better drainage of body fluids such as lymph fluid, improved blood flow to tissues and organs and much more.
- treatment techniques of this type are local, i.e. the therapeutic intervention by touch is always limited to a narrowly defined region of the body, although the effect of this therapeutic intervention can have an effect on the entire body of the patient, as is the case with osteopathic treatment techniques.
- Treatment methods of this kind do not consider the individual organs in isolation, but assume that pain in one part of the body can have its cause somewhere else. Internal organs and bones are connected by ligaments, muscles and nerves. If one part of the body is sick or injured, other organs can be disturbed in a kind of chain reaction. For example, kidney inflammation or kidney stones are not always to blame for kidney pain. It can also be the hip muscle on which the kidneys slide up and down about 600 times a day while breathing. If this muscle is tense, for example due to crooked posture, breathing and kidney function are also impaired. With osteopathic treatment techniques, targeted, gentle pressure massages are used with the Fingertips loosened muscle spasms, stretched ligaments and loosened bonds and adhesions. Good results are achieved for back, knee and jaw pain, diarrhea and constipation, migraines and menstrual disorders, for chronic sinus and bladder infections, for sudden hearing loss, tinnitus or asthma.
- Oscillating circuits are linked to certain physiological functions so that the term functional circuit appears more appropriate.
- the first functional group comprises the solid components of the spine, bones, teeth and nails as well as both legs, anus, rectum, colon, rectum, rectum and the prostate.
- the adrenal glands and the hormones adrenaline and noradrenaline can be assigned to this functional group.
- the blood and the general cell structure appear to be particularly linked to this functional group.
- the second group of functions includes the pelvic area, the reproductive organs, the kidneys and the bladder.
- the gonads, the ovaries, the testes and also the prostate as well as the estrogens and testosterone can be assigned to this functional group.
- the lymph, the digestive juices and the sperm seem to be particularly linked to this functional group with regard to the physiological linkage.
- the third group of functions includes the lower back, the abdominal cavity, the digestive system, the stomach, the liver, the spleen and the gallbladder.
- the pancreas and insulin can be assigned to this functional group.
- the vegetative nervous system seems to be particularly linked to this functional group with regard to the physiological connection.
- the fourth group of functions includes the upper back, the heart, the chest and chest cavity, the lower lung area as well as the skin and hands.
- the thymus gland and the thymus hormone can be assigned to this functional group.
- the blood circulation system appears to be particularly linked to this functional circuit.
- the fifth group of functions includes the lungs, the bronchi, the esophagus, the speaking apparatus, the throat, the neck, the jaw and the cheekbones.
- the thyroid and parathyroid glands as well as the hormone thyroxine can be assigned to this functional group.
- the sixth function group includes the cerebellum, ears, nose, sinuses, eyes, forehead and face.
- the pituitary gland as well as the hormone vasopressin (adiuretin) and pituitrin can be assigned to this functional group.
- the nervous system seems to be particularly linked to this functional group.
- the seventh function group includes the cerebrum and the skull cap.
- the pineal gland (epiphysis) as well as the hormone serotonin (enteramine) and melatonin can be assigned to this functional group.
- the first function group could use a frequency band from 31 Hz to 33 Hz
- the second function group a frequency band from 35.5 Hz to 37.5 Hz
- the third function group a frequency band from 40 Hz to 42.5 Hz
- the fourth function group a frequency band from 44.5 Hz to 46.5 Hz
- a frequency band from 49 Hz to 51 Hz is assigned to the fifth function circuit
- a frequency band from 54 Hz to 56 Hz to the sixth function circuit and a frequency band from 58.5 Hz to 60.5 Hz to the seventh function circuit.
- the aim of the invention is therefore a therapeutic treatment device which uses this fact and allows stimulation of individual functional circuits via their resonance frequencies. This goal is achieved by implementing the measures according to claim 1.
- Claim 1 provides a therapeutic treatment device with a support surface for the patient, in which at least one sound body is attached below the support surface, which generates sound waves with a frequency below 100 Hz, which are within predetermined, discrete frequency bands, and an operating unit with several control elements To control the at least one sound body is provided, in each of which an operating element is assigned to a given, discrete frequency band below 100 Hz and enables its selection.
- the resonance frequencies of the functional circuits are in the individual frequency bands. Provided by seven functional groups it is assumed that seven frequency bands will be provided, within each of which the resonance frequency of a functional circuit lies. Although physical systems have very sharply defined resonance frequencies, this is not the case with the biological functional circuits in question, so that we speak of frequency bands here.
- the operating unit makes the at least one sound body easy to operate, since the operator only has to actuate an operating element, for example a push button, a switch or a selection field of a corresponding software program, which can be selected by means of a computer mouse, in order to select a specific frequency band.
- an operating element for example a push button, a switch or a selection field of a corresponding software program, which can be selected by means of a computer mouse, in order to select a specific frequency band.
- Claim 2 provides an advantageous embodiment of the treatment device, according to which exactly two sound bodies are provided. Expediently, one of them will be arranged below the support surface in such a way that, when a patient is lying on the support surface, he is below the pelvic region of the patient and the second comes to lie below the chest area. This allows the patient's entire body to be optimally irradiated.
- Claims 4 to 10 specify frequency bands for a choice of seven functional circuits.
- control unit is equipped with a control element for amplitude modulation of the sound waves of the at least one sound body.
- Claims 12 to 15 provide that a sine generator and a pulse shaper are provided, the pulse shaper converting the sine waves generated by the sine wave generator into a sawtooth wave, square wave, triangular wave or a pulsed wave.
- the pulse shaper converting the sine waves generated by the sine wave generator into a sawtooth wave, square wave, triangular wave or a pulsed wave.
- these different pulse shapes have different therapeutic properties and thus enable optimization possibilities in therapeutic practice.
- the at least one sound body of the treatment device according to the invention is controlled, for example, via a commercially available CD player, the CD used containing audio frequencies as audio information within the frequency bands specified above. Therefore, claim 16 claims storage media for audio signals, such as CDs, for use with a therapeutic treatment device according to claim 1, wherein the audio signals essentially Have frequencies that are within predetermined, discrete frequency bands below 100 Hz.
- FIG. 1 is a schematic representation of an embodiment of a treatment device according to the invention
- Fig. 2 is a block diagram of an embodiment of the control unit and connected sound body
- Fig. 3 is a block diagram of another embodiment of the control unit using a pulse shaper and connected sound body.
- a support surface is initially provided which, according to the embodiment of FIG. 1, is formed from a solid, stable support plate 2 and an elastic bed layer 3, for example from a foam material.
- At least one sound body 1 is fastened below the support plate 2, which is preferably made of wood.
- 2 shows an embodiment in which two sound bodies 1 are used, the sound bodies being arranged below the support plate 2 such that when a patient is lying on the bed 3, a sound body 1 below the patient's pelvic area and the second sound body 1 comes to rest below the chest area of the patient.
- the head of the seated patient is supported, for example, by a cushion or a neck support 7.
- the sound bodies 1 can also be fastened, for example, on rails below the support plate 2 in order to make the sound bodies 1 displaceable and thus adapt to the respective patient allow (indicated in Fig. 1 with the horizontal arrows).
- Fig. 1 shows only the simplest design variant of a support surface, but different shapes are conceivable, so in practice a curved design of the support surface is advantageous, the shape of the support surface adapting to the curvature of the spine and ensuring support for the head.
- the lying layer 3 can also be made somewhat higher in the area that comes to lie below the spine of a patient lying on it, so that the muscles surrounding the spine are subjected to less pressure and can thereby relax better.
- the sound bodies 1 are loudspeakers which are particularly suitable for the reproduction of frequencies below 100 Hz. Loudspeakers of this type are also known as "subwoofers". According to the invention, however, the sound bodies 1 are mounted on the support plate 2 without a membrane, as a result of which the vibrations are transmitted directly to the support plate 2. These vibrations are transmitted directly to the patient's body and are in the form of a low frequency - Vibrations can be felt: As a result of the direct transmission of these vibrations to the body instead of an acoustic perception, these vibrations are also not subject to cognitive filtering If two sound bodies 1 are provided, the interference of the vibrations generated in the patient's body has a reinforcing effect.
- the sound bodies 1 are connected to a connection socket 6 and to the control unit 4 via cables 5.
- the control unit 4 can be a corresponding one Act control panel with a control panel 8, in which controls such as switches, push buttons or buttons 9, 14 and knobs 10 are provided.
- the control of the sound bodies 1 can also be carried out via a computer, the settings made by the control elements 9, 14, 10 being able to be carried out with a mouse click.
- the operating unit 4 would be a computer.
- “essentially” means that, for example, other audio signals could also be played back that have a relaxing rather than therapeutic effect, such as the sound of the sea or the like.
- FIGS. 2 and 3 an embodiment according to FIGS. 2 and 3 is assumed.
- an operating unit 4 with an operating panel 8 is provided.
- the control panel 8 will enable the selection of the frequencies corresponding to these functional circuits, for example by actuating the corresponding control element 9, for example a key 9.
- This will set an oscillator 11, for example, when a first key 9 is actuated it generates a sinusoidal voltage with a frequency in the range from 31 Hz to 33 Hz.
- This voltage is amplified by an amplifier 12 and supplied to the sound bodies 1, which stimulates the patient's first functional circuit.
- the amplifier 12 can be adjusted via an operating element 10, for example a rotary knob 10, on the operating panel 8 and, in practical implementation, will enable an output signal with an output of 20-100 watts.
- the control element 10 enables thus the amplitude modulation of the sound waves generated by the sound bodies 1. As a result, different sensitivities of patients can be taken into account, or the therapeutic intervention can be designed to differing degrees.
- 9 different frequencies can be generated in succession by actuating different keys, whereby different functional groups of the patient are addressed in each case.
- a key 9 can also be provided which successively generates all frequencies of the seven functional circuits, which the patient perceives as a "wave" starting with low-frequency vibrations which become increasingly higher-frequency and finally end again at low-frequency.
- each button 9 is assigned a specific frequency within the corresponding frequency band by suitable design of the electronic components, so that when this button 9 is actuated, this predetermined frequency is always generated in the course of therapeutic practice. In the course of the application, provision is therefore generally not made to vary the frequency assigned to a specific key 9 within the corresponding frequency band.
- the variability of a frequency within the corresponding frequency band is rather the manufacture of the treatment device significant. In principle, however, it is conceivable to enable the therapist by means of a corresponding controller to also variably design the frequency assigned to a specific key 9 within the corresponding frequency band, for example to optimize a therapeutic effect.
- the embodiment according to FIG. 2 Due to the use of a sine generator, the embodiment according to FIG. 2 generates 11 sound waves which are based on sine vibrations. Sounds of this type sound very pure and aesthetic, but have no overtones. It has now emerged in therapeutic practice that vibrations rich in overtones are advantageous in some cases. Therefore, the embodiment according to FIG. 3 additionally provides a pulse shaper 13, which converts the sinusoidal oscillations of the oscillator 11 into a sawtooth oscillation, which is subsequently amplified by the amplifier 12 and fed to the sound body 1. Sawtooth vibrations are rich in overtones and contain the complete overtone series of even and odd overtones. An additional therapeutic effect is attributed to these overtones.
- pulse shapers 13 can also be provided, which generate square-wave oscillations from sine oscillations. Rectangular waves are also very rich in overtones, even though the even-numbered overtones are missing.
- the pulsed sound that is produced with it can bring therapeutic advantages.
- pulse shapers 13 can also be provided, which generate pulses with variable pulse widths, which also changes the overtone content greatly. For example, sonication with short pulses can bundle the energy input over short time intervals, which can sometimes have therapeutic advantages. It is also conceivable to provide a pulse shaper 13 which forms triangular impulses.
- Triangular impulses are perceived acoustically as "soft” and not as aggressive as rectangular impulses with a short pulse duration.
- a large number of different pulse forms are possible, which, depending on the overtone content, resonance properties with the respective function circuits or impulse-characteristic energy input, enable different optimization options in therapeutic practice.
- an embodiment of the treatment device according to the invention can also provide a plurality of pulse shapers 13, between which one can in each case be selected using the operating element 14.
- the therapist can define an individual sound reinforcement program by addressing different functional groups by selecting different frequencies. Without wishing to be bound by any particular theory, it is assumed that the deep relaxation achieved and the energy introduced by the sound waves, which, for example, transform into heat or restructure tissues, ligaments, filaments or muscles, achieve a therapeutic effect. Up to the day of registration, good results could be demonstrated for back, knee, hip and jaw pain, diarrhea and constipation, migraines and menstrual complaints as well as for chronic sinus and bladder infections.
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rehabilitation Therapy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Percussion Or Vibration Massage (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0136003A AT413077B (de) | 2003-08-29 | 2003-08-29 | Therapeutisches behandlungsgerät |
| PCT/AT2004/000294 WO2005020869A1 (de) | 2003-08-29 | 2004-08-27 | Therapeutisches behandlungsgerät |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1658032A1 true EP1658032A1 (de) | 2006-05-24 |
| EP1658032B1 EP1658032B1 (de) | 2015-03-25 |
Family
ID=34229707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP04761018.3A Expired - Lifetime EP1658032B1 (de) | 2003-08-29 | 2004-08-27 | Therapeutisches behandlungsgerät |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20080214973A1 (de) |
| EP (1) | EP1658032B1 (de) |
| AT (1) | AT413077B (de) |
| WO (1) | WO2005020869A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2106253B1 (de) * | 2007-01-10 | 2016-05-18 | TIPA Tinnitus Corporation Pty Ltd | Behandlung von tinnitus |
| DE102007003361A1 (de) | 2007-01-17 | 2008-07-31 | Patex Group Ltd. | Vibrationstherapievorrichtung |
| US20090036805A1 (en) * | 2007-08-03 | 2009-02-05 | The Purrfect Device Inc. | Method and Apparatus for Providing an Animal Vocalization Driven Massage Device |
| DE102008026629A1 (de) * | 2008-06-04 | 2009-12-10 | Ernst Radetzky | Behandlungsvorrichtung, insbesondere für Bandscheibenerkrankungen |
| US20110004048A1 (en) * | 2009-07-03 | 2011-01-06 | Henry Brunelle | Therapy devices and domestic/commercial therapy system |
| EP2507773A1 (de) | 2009-12-02 | 2012-10-10 | Nestec S.A. | Getränkezubereitungsautomat mit umgebungsemulationsfunktion |
| CN102821732B (zh) * | 2010-04-08 | 2015-03-11 | 皇家飞利浦电子股份有限公司 | 声音按摩系统 |
| ITGO20120002A1 (it) * | 2012-03-22 | 2013-09-23 | Diego Kriscak | Lettino vibroacustico per la riduzione della cellulite |
| CN105979821B (zh) * | 2013-12-11 | 2019-05-10 | 艾尔高莫申公司 | 用于铰接床中的按摩和产生音频的振动系统 |
| US20160089298A1 (en) | 2014-09-29 | 2016-03-31 | Otolith Sound Inc | Device for Mitigating Motion Sickness and Other Responses to Inconsistent Sensory Information |
| US11284205B2 (en) | 2016-11-14 | 2022-03-22 | Otolith Sound Inc. | Systems, devices, and methods for treating vestibular conditions |
| US20180133102A1 (en) * | 2016-11-14 | 2018-05-17 | Otolith Sound, Inc. | Devices And Methods For Reducing The Symptoms Of Maladies Of The Vestibular System |
| US10398897B2 (en) | 2016-11-14 | 2019-09-03 | Otolith Sound Inc. | Systems, devices, and methods for treating vestibular conditions |
| CN110899076A (zh) * | 2019-10-11 | 2020-03-24 | 泉州极简机器人科技有限公司 | 床板的振动方法及装置 |
| CH719075A9 (fr) * | 2021-10-19 | 2023-06-30 | Vitality Universe Sarl | Système et méthode sonores de traitement des acouphènes. |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1063871A (en) * | 1962-07-05 | 1967-03-30 | George Walter De La Warr | Improvements relating to multi-frequency signal generating apparatus |
| US3253077A (en) * | 1963-12-12 | 1966-05-24 | Park Baker Electronic Dev Corp | Electrical musical instrument keying circuitry |
| US4112923A (en) * | 1976-08-24 | 1978-09-12 | Tomecek Jerry J | Antonomic transcutaneous affect device |
| DE3541350A1 (de) * | 1985-11-22 | 1987-06-04 | Pius Voegel | Therapiegeraet fuer den menschlichen koerper |
| US5101810A (en) * | 1986-03-19 | 1992-04-07 | Vibroacoustics A/S | Apparatus and method for therapeutic application of vibro-acoustical energy to human body |
| JPS6449559A (en) * | 1987-08-20 | 1989-02-27 | Toshio Takagi | Massager operated by acoustic signal |
| DE3825454A1 (de) * | 1988-07-27 | 1990-02-01 | Gfpe Verlag & Seminar | Liege |
| FI81959C (fi) * | 1988-10-24 | 1991-01-10 | Salomo Murtonen | Anordning foer infoering av vibration i en maenniskokropp. |
| US5035235A (en) * | 1990-06-25 | 1991-07-30 | Chesky Kris S | Music vibration table and system |
| NL9300938A (nl) * | 1993-06-01 | 1995-01-02 | Lena De Visser | Inrichting voor het toedienen van geluidsgolven en/of een magnetisch veld aan een patiënt. |
| CA2131950A1 (en) * | 1993-09-16 | 1995-03-17 | Kazumi Masaki | Fm theta-inducing audible sound, and method, device and recorded medium to generate the same |
| US5695455A (en) * | 1995-09-29 | 1997-12-09 | Sound Related Technologies, Inc. | Hydro-acoustic massage system and method |
| IT1280961B1 (it) * | 1995-10-10 | 1998-02-11 | Istituto Deanna M Lanfranco Pe | Dispositivo e metodo per la modulazione delle funzioni biologiche. |
| US6011852A (en) * | 1995-10-19 | 2000-01-04 | Howard; Albert R. | Audio power amplifier device for micro-computers |
| FI106530B (fi) * | 1996-10-08 | 2001-02-28 | Kaarlo Ilmari Railo | Hierontalaite |
| US6544165B1 (en) * | 1999-07-23 | 2003-04-08 | Mcnew Barry | Method and apparatus for applying frequency vibrations therapeutically |
| DE10040611A1 (de) * | 1999-08-18 | 2001-04-19 | Helmut Janowski | Infraschall-Massageliege |
| US20030083599A1 (en) * | 2001-11-01 | 2003-05-01 | Zeev Kitov | Acoustic band vibration massage for muscle relaxation: method and device |
-
2003
- 2003-08-29 AT AT0136003A patent/AT413077B/de not_active IP Right Cessation
-
2004
- 2004-08-27 WO PCT/AT2004/000294 patent/WO2005020869A1/de not_active Ceased
- 2004-08-27 US US10/569,857 patent/US20080214973A1/en not_active Abandoned
- 2004-08-27 EP EP04761018.3A patent/EP1658032B1/de not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2005020869A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20080214973A1 (en) | 2008-09-04 |
| ATA13602003A (de) | 2005-04-15 |
| EP1658032B1 (de) | 2015-03-25 |
| WO2005020869A1 (de) | 2005-03-10 |
| AT413077B (de) | 2005-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AT413077B (de) | Therapeutisches behandlungsgerät | |
| DE68914466T2 (de) | Verfahren und vorrichtung zur verwendung von schwingungen am menschlichen körper. | |
| EP0224102B1 (de) | Gerät für Schallwellentherapie | |
| EP2515998B1 (de) | Verfahren zur kosmetischen hautglättung mittels magnetfeld | |
| DE102004006192B4 (de) | Vorrichtung zur Behandlung mit Magnetfeldern | |
| DE102011086231B4 (de) | Übertragung von Körperschallwellen in einen Körper | |
| DE102008018262A1 (de) | Chirurgisches Gerät mit Nervtesteinrichtung | |
| EP3991612B1 (de) | Vibroakustische einrichtung zur insbesondere menschlichen klang- und/oder vibrationsbehandlung | |
| DE202009002043U1 (de) | Massagesessel mit einer Geistesablenkungs-Funktion | |
| DE19605777A1 (de) | Liege, Decke oder dergleichen zur therapeutischen Behandlung von Lebewesen | |
| EP1946736A1 (de) | Vibrationstherapievorrichtung | |
| EP2636392A1 (de) | Vorrichtung zur Tinnitusbehandlung | |
| AT409932B (de) | Magnetfeldgenerator für eine spule zur behandlung von menschlichem, tierischem oder pflanzlichem gewebe | |
| AT509544B1 (de) | Therapeutische behandlungsliege | |
| EP2153869B1 (de) | Befeldungsgerät zur Befeldung von Körperteilen von Lebewesen mit elektromagnetischen Wellen | |
| DE102008032232A1 (de) | Behandlungsliege | |
| DE102010022603A1 (de) | Stimulationsgerät | |
| DE102004055277A1 (de) | Elektrisches Therapiegerät mit programmierbarer und speicherbarer modulierter Mittelfrequenzträgerwelle | |
| DE10100385A1 (de) | Beeinflussungsvorrichtung zur therapeutischen Beeinflussung wenigstens von Teilbereichen eines Lebewesens | |
| EP1491228A2 (de) | Vorrichtung zur Beschallung einer Person | |
| DE202005009361U1 (de) | Knochenleitungshörgerät mit Doppelmagnetankopplung | |
| DE20208228U1 (de) | Kombiniertes Frequenz-Modulations-, Transfer-, und Transformations-System zur Erzeugung von phasengerechten (harmonikalen) akustoelektro-magnetischen Feldern in lebenden Organismen | |
| DE202004002685U1 (de) | Multifunktionales medizinisches elektrotechnisches Gerät | |
| AT522225B1 (de) | Vorrichtung zur applizierung von vibrationssignalen | |
| EP2363164B1 (de) | Therapeutische Behandlungsliege |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20060227 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| INTG | Intention to grant announced |
Effective date: 20140711 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: VON OTHEGRAVEN, ACHIM Owner name: GRACENT AG, |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: VON OTHEGRAVEN, ACHIM Inventor name: GRACENT AG, |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: VON OTHEGRAVEN,ACHIM |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| RIN2 | Information on inventor provided after grant (corrected) |
Inventor name: VON OTHEGRAVEN, ACHIM |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: GERMAN |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 502004014860 Country of ref document: DE Effective date: 20150507 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 717419 Country of ref document: AT Kind code of ref document: T Effective date: 20150515 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150325 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150626 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150325 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150325 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150325 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150325 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150727 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150325 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150325 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 502004014860 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150325 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20160105 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150325 Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150827 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150325 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150325 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150827 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150325 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20040827 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150325 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150831 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150325 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20180822 Year of fee payment: 15 Ref country code: FR Payment date: 20180824 Year of fee payment: 15 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20180828 Year of fee payment: 15 Ref country code: SE Payment date: 20180827 Year of fee payment: 15 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20190219 Year of fee payment: 15 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20190822 Year of fee payment: 16 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20190826 Year of fee payment: 16 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20190901 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 717419 Country of ref document: AT Kind code of ref document: T Effective date: 20190827 |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20190827 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190827 Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190828 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190831 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190901 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190827 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 502004014860 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200831 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200831 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210302 |